After an initial four-armed, controlled trial demonstrated a 3.3% rate of infarction in the aspirin arm (that is, four infarcts in this group) and a 0.8% rate in the heparin arm (that is, one infarct), Theroux et all devised a second controlled trial between heparin and aspirin. The joint counting of events in the heparin and aspirin arms of the first trial and in the second trial shows nine events among the aspirin patients (four in the first trial, five in the second trial) and two events among the heparin patients (one in the first trial, one in the second trial).
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Aspirin Versus Heparin in the Acute Phase of Unstable Angina
After an initial four-armed, controlled trial demonstrated a 3.3% rate of infarction in the aspirin arm (that is, four infarcts in this group) and a 0.8% rate in the heparin arm (that is, one infarct), Theroux et all devised a second controlled trial between heparin and aspirin. The joint counting of events in the heparin and aspirin arms of the first trial and in the second trial shows nine events among the aspirin patients (four in the first trial, five in the second trial) and two events among the heparin patients (one in the first trial, one in the second trial).
This study1 on aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina raises the following issues.
(1) What was the conditional probability to observe five events in the aspirin and one in the heparin group among the 245 additionally randomized patients, taking into account the four events and one event counted in the heparin and aspirin arms of the initial trial? Therefore, what is the true probability level of significance for the overall comparison of the heparin and aspirin groups in what is, despite the quotation of the report of O'Brien and Fleming2 among the references, not really a trial with interim analyses but an overall analysis of two successive trials?
(2) The authors state that "A Cox regression logistic analysis was used to correct the baseline differences between the two groups" as a part of a legend of survival curves. As similar as the two Cox's models are (one is the linear logistic regression model3 and anotherusually quoted as "Cox's model" -is a nonlinear survival data regression model4), the reader may wonder which one has been used. Furthermore, the small number of analyzed events does not necessarily allow for performing those multivariate analyses.
(3) The so-called factorial analysis, which is a comparison between the heparin and nonheparin groups obtained by the reunion of both trials, is incorrect because both groups are not balanced for aspirin. The same is true for the comparison between the aspirin and nonaspirin groups.
It is not certain that the main conclusion of this study is affected by its poor statistical analysis, but it is unfortunate to read such statistical vagaries in Dr Theroux's report. 
Repby
The concerns raised by Drs Moise and Roos on our article1 were already recognized in our original manuscript. We thank them for their comments, which might help in understanding the significance of our results, the limitations, and the important clinical impact.
The extension trial was performed after a recommendation of the Policy Board to enroll an additional 245 patients randomized to aspirin plus placebo-heparin or to heparin plus placebo-aspirin using the same protocol as in the initial study2 but deleting the study groups with two placebos and with the combination of the two active drugs. We recognized that this extension trial had not been planned in the original study design, and for this reason we described the study as the results of two consecutive cohorts of patients enrolled with one interim look at the data.
The Cox's model used was a log-linear logistic regression. Clearly, the study had no factorial design because two parallel groups were studied. The analysis of heparin versus nonheparin patients and of aspirin versus nonaspirin patients was presented as an extended analysis (sic) for the purpose of providing the readers all available information and was not used for the interpretation of the data.
Whether heparin, aspirin, or a combination of both should be used in unstable angina is an important problem that confronts cardiologists on a daily basis. Our early study2 and the trial of Neri Semneri et a13 clearly indicate that a continuous infusion of heparin reduces the incidence of refractory angina in unstable angina. The more recently published results of the ATACS Trial by Cohen et al,4 which included a meta-analysis, strongly suggest that the addition of heparin to aspirin reduces the risk of fatal and nonfatal myocardial infarction after 5 days of treatment from 3.3% to 1.6% (relative risk, 0.44; 95% confidence intervals, 0.21 to 0.93). A large, definitive clinical trial comparing heparin and aspirin in unstable angina has not been done and to our knowledge is not planned. Such a trial was recommended in our report. Based on the relative risk observed and on the homogeneity of the results in our two consecutive cohorts of patients, the sample size for this more definitive trial should be approximately 500 patients per group. In the absence of such a study, our data represent the best available guidance for the clinician. We recommend heparin to reduce the risk of myocardial infarction in unstable angina. Pierre Th6roux, MD Institut de Cardiologie de Montreal Montreal, Quebec, Canada
Outflow Tract Obstruction and Failed Mitral Repair I would like to make some comments concerning the article by Lee et al.1 I found their work very interesting, but some the echocardiographic methods as well as interpretation of the results produce confusion and raise some questions. The authors made several measurements of the left ventricle, mitral valve, and mitro-aortic angle by monoplane transesophageal echocardiography (TEE). In Fig 2, they summarize by a diagram how the mitro-aortic angle was measured by TEE. In our own experience this approach was inappropriate for the following reasons.
(1) Even with the widest-angle aperture, we usually were unable to simultaneously capture both mitral and aortic annulus planes; in other terms, we did not have the insertion of two aortic cusps and two mitral leaflets on the same echo view. Annulus plane definition needs a section across two leaflets' or cusps' insertion. It is therefore doubtful that mitro-aortic angle has been determined by TEE as it is stated in this diagram.
(2) Five-chamber transesophageal view gives an oblique section across the heart structures. This section is not perpendicular and does not cross the mid part of both annuli. Mitral annulus size was therefore estimated according to an oblique section plane and called mitral annulus dimension. This dimension is not the true anteroposterior diameter.
(3) Left atrial size has great variations if we compare the preoperative with the postoperative situation. These variations induce changes of the TEE echo beam angle on the mitral annulus. The preoperative measurements were compared with those after the first and/or the second repair without any estimation of the left atrial size. This is the probable explanation of the following confusing results (see below).
The authors did not find any anterior displacement of the posterior part of the mitral annulus. Looking at Table 1 , a striking paradox appears: Patients with systolic anterior motion had no reduction of the annulus size, but when the prosthetic ring was removed, the annular dimension was significantly reduced (P=.01). If we should follow the same logic, prosthetic ring implant for mitral insufficiency will not change the annular dimension leading to systolic anterior motion, but removal of the ring will reduce the annular dimension and relive the obstruction.
These paradoxical results seem to result from (1) an inappropriate echo method and (2) a too-small group of patients with different types of annuloplasty. For this purpose we found the transthoracic approach better. Changes in the mitro-aortic angle were described23 in several situations after mitral valve replacement surgery and seem to be determined by an important annular reduction. If annular size is reduced by a prosthetic implant, the anteroposterior diameter will be also reduced. On the other hand, this is the aim of any annuloplasty when indicated. This reduction will produce an anterior displacement of the part of posterior left ventricular wall that represents the true mitral annulus.
The authors found that the coaptation between mitral leaflets was more anterior after mitral valve repair than before. They interpreted this finding as the responsible mechanism for obstruction, but they did not explain why. In our previously published article,4 this finding was already demonstrated but as an end result that represents the last link clearly creating subaortic obstruction: "... size reduction of the mitral annulus by the prosthetic ring produced an anterior (toward the aorta) displacement of the posterior left ventricular wall and the posterior mitral leaflet. The degree of anterior displacement was directly related to the mitral annular dilation versus the prosthetic ring shape."
When multiple modifications are linked together, a close relation can oversimplify the cause-to-effect mechanism, therefore leading to misinterpretation. Serban Mihaileanu, MD Cardiovascular Surgery Department Broussais Hospital, Clinique Leriche
Paris

Reply
We thank Dr Mihaileanu for his comments regarding our article.' In response to his letter, we have the following comments.
Dr Mihaileanu had concerns regarding the use of transesophageal echocardiography in the measurements of cardiac dimensions and the mitroaortic angle. In our study, we did not encounter great difficulty in obtaining transesophageal echo images displaying both the left ventricular outflow tract and the mitral valve annulus. We believe that transesophageal echocardiography, with its greater resolution, allowed us to make the measurements that we reported with a greater degree of reproducibility and accuracy than transthoracic echocardiography.
Because the true anteroposterior orientation may vary slightly among patients and the annulus is saddle shaped,2 it is likely that transthoracic and transesophageal echocardiography do not provide identical reference points for measurement for the mitral annulus dimension that are comparable between patients. However, with either method, measurements obtained in a single plane will be consistent and reflect change compared with previous measurements in the same plane with the same imaging modality. We have labeled this measurement as mitral annulus dimension and agree that it may not be the true anteroposterior diameter. We are confident that transesophageal echocardiography consistently and accurately measured the change in mitral annular dimension in these patients at various times during mitral valve surgery, when transthoracic echo would obviously be inapplicable.
With regard to the change of absolute mitral annular dimension before and during the occurrence of systolic anterior motion, Table 1 clearly shows a reduction from 33.4 to 30.7 mm (P<.06), resulting from various leaflet procedures and annuloplasty. With revision of the annuloplasty, there is no significant change in the annular dimension (to 29.4 mm, P=NS). Dr Mihaileanu pointed out that when 33.4 mm is compared with 29.4 mm, there is a significant drop in annular dimension (P<.01), which is true. Because the annuloplasty had been partially or completely removed at that time, the reduction in annular dimension evidently resulted from the leaflet procedure including quadrilateral resection of the posterior leaflet. The reduction in annular dimension probably resulted from the pledgetted sutures used to close the annular side of the posterior leaflet resection.
We appreciate Dr Mihaileanu's remarks and the insights of the Broussais group into the mechanism of this complication after mitral valve repair.3 As reflected by our use of the sliding posterior leaflet advancement technique that they have described,4 our philosophies are not widely disparate. This procedure reduces the posterior annulus-to-coaptation line distance and increases septum-to-coaptation line distance. Although patients with milder dynamic obstruction do not need this maneuver and can often be managed medically with volume replacement and avoidance of positive inotropes,56 patients with large redundant posterior leaf-
